Cancer Neuroscience Training Program

摘要 光遗传学和单细胞基因组学等当代新技术表明，电活动 神经元刺激成人和儿童胶质瘤的生长。相反，癌症和癌症疗法会改变 神经系统的形态和功能(例如，与癌症治疗相关的认知障碍俗称 “化学雾”或“化学雾”)。肿瘤和神经系统之间的双向对话定义了 新兴的科学学科被称为“癌症神经科学”。布里格姆大学神经科 和妇女医院(BWH)以及哈佛医学院神经生物学系 (HMS)，在这一新领域提出一个综合性的、首屈一指的博士后培训计划。该计划将是 由临床科学家Tracy Batchelor医学博士(BWH神经病学主席)和基础科学家Michael共同领导 格林伯格博士(哈佛脑科学倡议联席主任)。29名导师将从 Dana-Farber/哈佛癌症中心和哈佛脑科学倡议。这将是一门基础科学 程序。拥有博士和/或医学博士学位的候选人将有资格，但不会有临床培训。 我们要求每年为6名博士后研究员提供支持，以服务于为期2年的任命。该计划将 培养这些学员的科学发展和专业发展。为了科学 开发，该计划将为博士级别的基础科学家带来神经发育方面的技能， 电生理学、神经电路、光遗传学、脑代谢和神经化学 临床/转化性研究人员致力于脑原发和转移癌的研究。用于实验室 研究，研究员将被教导以确定重要的问题和方法，将推动该领域向前发展 并提供影响癌症治疗的翻译机会。在专业发展方面，我们会 为受训者提供(I)完善和加强其恩赐精神和科学交流的机会 技能；(2)个人发展计划；(3)个别博士后指导委员会；(4)定制 为学员提供获得指导和教学经验的机会，具体取决于他们的职业目标。 计划主任和联席主任将与培训监督委员会和 外部咨询委员会。与莫尔豪斯医学院和 马萨诸塞大学波士顿分校(纽约最大的少数民族学生高等教育中心 英格兰)将帮助确定招募代表人数不足的少数族裔加入该计划的方法，并保持 为这些实习生提供友好的环境。衡量学员满意度的其他策略、量化 结果，并评估该计划的有效性，将包括对受训者和 导师，以及离职面试和校友面试。以最先进的核心设施的形式提供的机构支持， 支持T32特定培训活动和EAB年度会议的技术平台和资金将 显著加强培训计划。

Abstract Contemporary new technologies such as optogenetics and single cell genomics show that electrically active neurons stimulate growth of adult and pediatric gliomas. Conversely, cancers and cancer therapies alter nervous system form and function (e.g., cancer therapy-related cognitive impairment colloquially known as ‘‘chemobrain’’ or ‘‘chemofog”). The two-way dialogue between tumors and the nervous system defines an emerging new scientific discipline termed “Cancer Neuroscience”. The Department of Neurology at Brigham and Women’s Hospital (BWH), together with the Department of Neurobiology at Harvard Medical School (HMS), propose an integrative, first-in-kind postdoctoral training program in this new field. The Program will be co-led by a clinician scientist, Tracy Batchelor, M.D. (Chair of Neurology at BWH) and a basic scientist Michael Greenberg, Ph.D. (co-director, Harvard Brain Science Initiative). A faculty of 29 mentors will be drawn from the Dana-Farber/Harvard Cancer Center and from the Harvard Brain Science Initiative. This will be a basic science program. Candidates with Ph.D. and/or M.D. degrees will be eligible but there will be no clinical training. We request support for 6 postdoctoral fellows per year to serve 2-year appointments. The Program will foster both scientific development and professional development of these trainees. For Scientific Development, the Program will bring doctorate level basic scientists with skill sets in neural development, electrophysiology, neural circuitry, optogenetics, brain metabolism and neurochemistry into the laboratories of clinical/translational investigators working on primary and also metastatic cancers of the brain. For laboratory research, fellows will be taught to identify important questions and approaches that will move the field forward and provide translational opportunities to impact cancer treatment. For professional development, we will provide trainees with (i) opportunities to refine and enhance their grantsmanship and scientific communication skills; (ii) individual Development Plans; (iii) individual postdoctoral mentoring committees, and (iv) customized opportunities for trainees to acquire experience in mentoring and teaching depending on their career goals. The program Director and co-Director will work closely with a Training Oversight Committee and an External Advisory Board. Collaborative relationships with Morehouse School of Medicine and with the University of Massachusetts-Boston (the largest center of higher education for minority students in New England) will help identify ways to recruit underrepresented minorities into the program and to maintain a welcoming environment for these trainees. Additional strategies to measure trainee satisfaction, quantify outcomes, and evaluate the effectiveness of the program will include annual surveys from trainees and mentors, as well as exit and alumni interviews. Institutional support in the form of state-of-art core facilities, technology platforms and funds to support T32-specific training activities and yearly EAB meetings will significantly enhance the training program.